Kahimmune Therapeutics has secured a licensing agreement with Gustave Roussy and SATT Paris-Saclay to develop a vaccine targeting colorectal and pancreatic cancers. This collaboration marks a significant step in advancing innovative cancer therapies.

A new CDC report highlights that increased screening could significantly reduce colorectal cancer rates, which is currently the second leading cause of cancer deaths in the U.S. The report indicates a decline in both incidence and mortality rates among adults.

A CDC study reveals that over 75% of primary care physicians prefer in-office fecal occult blood tests for colorectal cancer screening, despite home-based tests being more accurate. This highlights a significant gap in screening practices that could impact early detection efforts.

The CDC has allocated $22 million to support colorectal cancer screening programs across 26 states and tribal organizations, targeting low-income individuals aged 50-64 who are underinsured or uninsured. This initiative aims to improve access to vital screening services for a vulnerable population.

A new national colorectal cancer screening demonstration program aims to enhance early detection and reduce mortality rates. This initiative addresses the significant public health challenge posed by colorectal cancer, the second leading cancer killer in the U.S.

A new CDC study reveals that colorectal cancer screening rates are on the rise among U.S. adults, although disparities remain in certain populations. Continued efforts are needed to address these gaps and ensure equitable access to screening.